Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a day after data from an early-stage study dragged its stock 7% lower.

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone mineral density that could undermine its ability to compete in the fast-growing sector.

Olivia Brayer, Cantor Fitzgerald, joins 'Fast Money' to discuss Amgen shares sliding on bone density data. Cowboys 9x All-Pro predicted to cut ties with Dallas, join Bears Florida’s Retirees Are Fleeing: Experts Predict These 5 States Will Be Top Retirement Spots in 10 Years The most influential female singers of the last decade I ditched my car and hopped on a train to the Grand Canyon.